New learnings on the pathophysiology of RA from synovial biopsies

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 334-344

  Pitzalis, Costantino ^a   Kelly, Stephen ^a   Humby, Frances ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

rheumatoid arthritis; synovial pathobiology; targeted biologic therapies; ultrasound guided synovial biopsy

Indexed keywords

ABATACEPT; ACTIVIN A; OSTEOCLAST DIFFERENTIATION FACTOR; RITUXIMAB; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR INHIBITOR;

ADAPTIVE IMMUNITY; ARTHROSCOPY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DISEASE SEVERITY; HEMARTHROSIS; HUMAN; IMAGE ANALYSIS; IMMUNOGLOBULIN PRODUCTION; INFECTIOUS ARTHRITIS; JOINT BIOPSY; JOINT SWELLING; LOCAL ANESTHESIA; MEMORY CELL; NONHUMAN; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; SYNOVITIS; SYNOVIUM; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOPSY; HUMANS; SYNOVIAL MEMBRANE; SYNOVITIS; TREATMENT OUTCOME;

EID: 84875874716     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835fd8eb     Document Type: Review

References (89)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376:1094-1108; Epub 2010/09/28.
2. Emery P, McInnes IB, Van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:392-398; Epub 2007/12/21.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
4. Van de Sande MG, de Hair MJ, Van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011; 70:772-777.
5. Pitzalis C, Garrood T. From ubiquitous antigens to joint-specific inflammation: could local vascular permeability be the missing link Trends Immunol 2006; 27:299-302.
6. Cantaert T, De Rycke L, Bongartz T, et al. Citrullinated proteins in rheumatoid arthritis: crucial.but not sufficient! Arthritis Rheum 2006; 54:3381-3389.
7. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003; 48:64-71.
8. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nature Rev Rheumatol 2012; 8:656-664; Epub 2012/09/26.
9. Knevel R, Van Nies JA, le Cessie S, et al. Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Ann Rheum Dis 2013; 72:307-308.
10. Wick MC, Lindblad S, Klareskog L, Van Vollenhoven RF. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description. Ann Rheum Dis 2004; 63:848-852; Epub 2004/06/15.
11. Van de Sande MG, Gerlag DM, Lodde BM, et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis 2011; 70:423-427.
12. Scire CA, Epis O, Codullo V, et al. Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Res Ther 2007; 9:R101.
13. Parker RH, Pearson CM. A simplified synovial biopsy needle. Arthritis Rheum 1963; 6:172-176.
14. Saaibi DL, Schumacher HR Jr. Percutaneous needle biopsy and synovial histology. Bailliere's Clin Rheumatol 1996; 10:535-554.
15. Youssef PP, Kraan M, Breedveld F, et al. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis Rheum 1998; 41:663-669.
16. Kraan MC, Versendaal H, Jonker M, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998; 41:1481-1488.
17. Van Vugt RM, Van Dalen A, Bijlsma JW. Ultrasound guided synovial biopsy of the wrist. Scand J Rheumatol 1997; 26:212-214.
18. Koski JM, Helle M. Ultrasound guided synovial biopsy using portal and forceps. Ann Rheum Dis 2005; 64:926-929.
19. Koski JM, Saarakkala S, Helle M, et al. Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments. Ann Rheum Dis 2006; 65:1590-1595.
20. Marin F, Lasbleiz J, Albert JD, et al. Synovial biopsy under US guidance: technical considerations and results. Journal de radiologie 2006; 87:561-565.
21. Baeten D, Van den Bosch F, Elewaut D, et al. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999; 18:434-441.
22. Kane D, Veale DJ, FitzGerald O, Reece R. Survey of arthroscopy performed by rheumatologists. Rheumatology (Oxford) 2002; 41:210-215.
23. Kraan MC, Reece RJ, Smeets TJ, et al. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002; 46:2034-2038; Epub 2002/09/05.
24. Rooney T, Bresnihan B, Andersson U, et al. Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis. Ann Rheum Dis 2007; 66:1656-1660.
25. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167:1072-1080; Epub 2001/07/07.
26. Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005; 35:1347-1359.
27. Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010; 233: 267-285.
28. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 2003; 987:140-149.
29. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Rev Immunol 2006; 6:205-217.
30. Weyand CM, Kang YM, Kurtin PJ, Goronzy JJ. The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr Opin Rheumatol 2003; 15:259-266; Epub 2003/04/23.
31. Bugatti S, Manzo A, Bombardieri M, et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 2011; 13:440-448.
32. Corsiero E, Bombardieri M, Manzo A, et al. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012; 145:62-67.
33. Van der Pouw Kraan TC, Van Gaalen FA, Huizinga TW, et al. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 2003; 4:187-196.
34. Kasperkovitz PV, Timmer TC, Smeets TJ, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblastlike phenotype and high-inflammation synovitis. Arthritis Rheum 2005; 52:430-441.
35. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8:R171.
36. Tolboom TC, Van der Helm-Van Mil AH, Nelissen RG, et al. Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52:1999-2002; Epub 2005/06/30.
37. Buckley CD. Why does chronic inflammation persist: an unexpected role for fibroblasts. Immunol Lett 2011; 138:12-14.
38. Holt AP, Haughton EL, Lalor PF, et al. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 2009; 136:705-714.
39. Bradfield PF, Amft N, Vernon-Wilson E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4\+ and CD8\+ T cell migration within synovial tissue. Arthritis Rheum 2003; 48: 2472-2482.
40. Manzo A, Bugatti S, Caporali R, et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol 2007; 171:1549-1562.
41. Timmer TC, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007; 56:2492-2502.
42. Croia C, Serafini B, Bombardieri M, et al. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis 2012 [Epub 2012/12/27].
43. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Ann Rev Immunol 2007; 25:587-617.
44. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nature Rev Immunol 2001; 1:75-82.
45. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59:945-953.
46. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40:217-225.
47. Tsubaki T, Arita N, Kawakami T, et al. Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther 2005; 7:R825-R836.
48. Van Oosterhout M, Bajema I, Levarht EW, et al. Differences in synovial tissue infiltrates between anticyclic citrullinated peptide-positive rheumatoid arthritis and anticyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 2008; 58:53-60.
49. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39:115-124.
50. Kraan MC, Haringman JJ, Weedon H, et al. T cells, fibroblast-like synoviocytes, and granzyme B\+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004; 63:483-488.
51. Kraan MC, Haringman JJ, Post WJ, et al. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford) 1999; 38:1074-1080.
52. Van de Sande MG, Thurlings RM, Boumans MJ, et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time Ann Rheum Dis 2011; 70:700-703.
53. Thurlings RM, Wijbrandts CA, Mebius RE, et al. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum 2008; 58:1582-1589.
54. Klimiuk PA, Sierakowski S, Latosiewicz R, et al. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003; 62:472-475.
55. Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010; 22:307-315.
56. Dharmapatni AA, Smith MD, Crotti TN, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Therapy 2011; 13:R51.
57. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167:4710-4718.
58. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44:1003-1012.
59. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010; 233:301-312.
60. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996; 93:221-225.
61. Klarenbeek PL, de Hair MJ, Doorenspleet ME, et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 2012; 71:1088-1093.
62. Scheel T, Gursche A, Zacher J, et al. V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum 2011; 63:63-72.
63. Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6:e1.
64. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102:553-563.
65. Weyand CM, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis Res Ther 2005; 7 (Suppl 3):S9-S12.
66. Van der Pouw Kraan TC, Wijbrandts CA, Van Baarsen LG, et al. Responsiveness to antitumour necrosis factor alpha therapy is related to pretreatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008; 67:563-566.
67. Lindberg J, af Klint E, Catrina AI, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006; 8:R179.
68. Van Baarsen LG, Wijbrandts CA, Gerlag DM, et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010; 11:622-629.
69. Haringman JJ, Vinkenoog M, GerlagDM, et al. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R862-R867.
70. Wijbrandts CA, Vergunst CE, Haringman JJ, et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007; 56:3869-3871.
71. Canete JD, Celis R, Moll C, et al. Clinical significance of synovial lymphoid neogenesis and its reversal after antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68:751-756.
72. Badot V, Galant C, Nzeusseu Toukap A, et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R57.
73. Klaasen R, Thurlings RM, Wijbrandts CA, et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 2009; 60:3217-3224.
74. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
75. Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Therapeut 2010; 125:464-475.
76. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:772-778; Epub 2007/03/01.
77. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67:917-925.
78. KaVanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67:402-408.
79. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007; 56:3909-3918.
80. Hogan VE, Holweg CT, Choy DF, et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis 2012; 71:1888-1894.
81. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010; 62:3607-3614.
82. Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of nonresponse to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14:R95.
83. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68:1220-1227.
84. Kanbe K, Chen Q, Nakamura A, Hobo K. Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis. Clin Rheumatol 2011; 30:1407-1413; Epub 2011/09/13.
85. Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel. Cancer 2011; 117:1575-1582.
86. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16:5-24.
87. Ton E, Kruize AA. How to perform and analyse biopsies in relation to connective tissue diseases. Best Pract Res Clin Rheumatol 2009; 23: 233-255.
88. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertension 2005; 14:1-8.
89. Lindberg J, Wijbrandts CA, Van Baarsen LG, et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PloS One 2010; 5:e11310.